<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) comprise a group of clonal hemopoietic stem cell disorders characterized by ineffective hematopoiesis with an increased propensity to myeloid leukemic (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) transformation </plain></SENT>
<SENT sid="1" pm="."><plain>The underlying molecular basis for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and its leukemic evolution is unclear </plain></SENT>
<SENT sid="2" pm="."><plain>Except for patients with <z:e sem="disease" ids="C0795864" disease_type="Disease or Syndrome" abbrv="">17p syndrome</z:e>, loss of function of the p53 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene accounts for &lt;10% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cases </plain></SENT>
<SENT sid="3" pm="."><plain>Recently, mutations of the checkpoint gene, CHK2, the human homologue of the yeast CDS1 and RAD53 genes, have been reported in patients with <z:e sem="disease" ids="C0085390" disease_type="Neoplastic Process" abbrv="LFS">Li-Fraumeni syndrome</z:e> who also have <z:mpath ids='MPATH_458'>normal</z:mpath> p53 </plain></SENT>
<SENT sid="4" pm="."><plain>As p53 mutations are rare in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, we investigated the status of the CHK2 gene by reverse transcriptase-polymerase chain reaction (RT-PCR) in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (n=10) and patients in whom <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> had transformed into <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (n=3) </plain></SENT>
<SENT sid="5" pm="."><plain>In the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> group, we found one patient with a conserved mutation (<z:chebi fb="0" ids="32563">Lys--</z:chebi>&gt;Arg) in the forked head-associated (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FHA</z:e>) domain of the CHK2 coding sequence </plain></SENT>
<SENT sid="6" pm="."><plain>We also found a deletion in the CHK2 transcript in one patient from the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>--&gt;<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> group, resulting in a truncated protein lacking the kinase domain </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that alterations of CHK2 and possible involvement in the pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> may be a rare event </plain></SENT>
</text></document>